| Name | Title | Contact Details |
|---|
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.
Fisher and Paykel Healthcare Corporation Limited is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Holland Applied Technologies is a Burr Ridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue restoration. The company`s initial focus is the Bridge-Enhanced® ACL Restoration (BEAR®) Implant, which represents a paradigm shift in the treatment of ACL tears from reconstruction to restoration. The BEAR technology was pioneered by Martha Murray, M.D., founder of Miach Orthopaedics, at the Boston Children`s Hospital Department of Orthopedic Surgery, with initial research funding provided by the NFL Players Association, Boston Children`s Hospital and the National Institutes of Health.
RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. From home to hospital and ER to OR, RapidAI is leading the next evolution of clinical decision-making and patient workflow, bringing the end-to-end patient journey into focus. Based on intelligence gained from over 4 million scans in more than 2000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible, saving lives, time and money.